公开(公告)号：EP1370260B1

公开(公告)日：2010-11-24

申请号：EP02721032.7

申请日：2002-02-19

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： ARRHENIUS, Thomas, Chugai Biopharmaceuticals Inc. ,  CHENG, Jie Fei, Chugai Biopharmaceuticals Inc. ,  WILSON, Mark, Chugai Biopharmaceuticals Inc. ,  SERAFIMOV, Rossy, Chugai Biopharmaceuticals Inc. ,  NADZAN, Alex Chugai Biopharmaceuticals, Inc. ,  LOPASCHUK, Gary ,  DYCK, Jason

IPC分类号： A61K31/425 ,  C07D513/04 ,  C07D277/70 ,  A61P9/10 ,  A61P3/10

CPC分类号： A61K31/423 ,  A61K31/425 ,  A61K31/426 ,  A61K31/428 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541

摘要： The present invention relates to methods of treatment of certain metabolic diseases, and to novel compounds and their prodrugs, and/or pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds useful in treating such diseases. In particular, this invention relates to the use of novel compounds and compositions for treatment of cardiovascular diseases, diabetes, cancers, acidosis, and obesity through the inhibition of malonyl-CoA decarboxylase (MCD). These compounds have the formulae (I) and (II), wherein Y, C, R1, R2, R6, and R7 are defined herein.

公开(公告)号：EP1353662B1

公开(公告)日：2007-04-18

申请号：EP02703196.2

申请日：2002-01-22

申请人： CHUGAI SEIYAKU KABUSHIKI KAISHA

发明人： ARRHENIUS, Thomas Chugai Biopharmaceuticals, Inc. ,  CHEN, Mi Chugai Biopharmaceuticals, Inc. ,  CHENG, Jie Fei Chugai Biopharmaceuticals, Inc. ,  HARAMURA, Masayuki Chugai Biopharmaceuticals, Inc. ,  HUANG, Yujin Chugai Biopharmaceuticals, Inc. ,  NADZAN, Alex Chugai Biopharmaceuticals, Inc. ,  TITH, Sovouthy Chugai Biopharmaceuticals, Inc. ,  WALLACE, David Chugai Biopharmaceuticals, Inc. ,  ZHANG, Lin Chugai Biopharmaceuticals, Inc. ,  BROWN, Steve Chugai Biopharmaceuticals, Inc. ,  HARMON, Charles Chugai Biopharmaceuticals, Inc. ,  LOPASCHUK, Gary ,  DYCK, Jason

IPC分类号： A61K31/16 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/44 ,  A61K31/42 ,  A61K31/5375 ,  A61P3/04 ,  A61P3/10 ,  A61P9/10 ,  A61P35/00

CPC分类号： C07D231/06 ,  A61K31/16 ,  A61K31/165 ,  A61K31/17 ,  A61K31/175 ,  A61K31/18 ,  A61K31/197 ,  A61K31/221 ,  A61K31/275 ,  A61K31/40 ,  A61K31/41 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/4188 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/451 ,  A61K31/5375 ,  A61K31/5377 ,  C07C33/46 ,  C07C33/48 ,  C07C215/24 ,  C07C233/22 ,  C07C257/22 ,  C07C279/18 ,  C07C307/10 ,  C07C323/14 ,  C07C335/18 ,  C07D231/14 ,  C07D233/64 ,  C07D233/90 ,  C07D239/42 ,  C07D261/04 ,  C07D261/08 ,  C07D261/14 ,  C07D261/18 ,  C07D277/46 ,  C07D277/48 ,  C07D277/52 ,  C07D285/135 ,  C07D295/13 ,  C07D295/194 ,  C07D295/21 ,  C07D295/215 ,  C07D295/32 ,  C07D307/46 ,  C07D307/52 ,  C07D401/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D487/08 ,  C07F9/247 ,  C07F9/4021 ,  C07F9/6539

摘要： The present invention relates to methods for the prophylaxis, management and treatment of certain diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD) by the administration of a composition containing as an active ingredient a compound according to Formula I. In particular, the invention relates to methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the administration of a compound which inhibits malonyl-coenzyme A decarboxylase activity. The present invention also includes within its scope the novel process for the preparation of certain compounds.